Boehringer, Lilly tout late-stage data on key diabetes drug

Eli Lilly ($LLY) and its close diabetes drug development partner Boehringer Ingelheim laid out a slate of positive late-stage data for its diabetes treatment empagliflozin, a big step toward applying for regulatory approval this year. Report

document.addEventListener("googletagEvent", function() { googletag.cmd.push(function() { googletag.display('ad-slot_1__mobile'); }); });
Read more on